Antietumor necrosis factor-α therapy in uveitis

Survey of Ophthalmology

Volumn 60, Issue 6, 2015, Pages 575-589

  Cordero Coma, Miguel ^a,b   Sobrin, Lucia ^c,d  

^a Uveitis Unit University Hospital of León   (Spain)

^b UNIVERSITY OF LEÓN   (Spain)

^c MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adalimumab; Anti drug antibodies; Certolizumab; Etanercept; Golimumab; Infliximab; Pharmacogenomics of anti TNF ; Serum levels of anti TNF drug; Therapy; Tumor necrosis factor alpha; Uveitis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 22; INTERLEUKIN 4; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANGIOGENESIS; APLASIA; APOPTOSIS; APPLICATION SITE ECZEMA; ATHEROMA; ATHEROSCLEROSIS; BEHCET DISEASE; BLOOD EYE BARRIER; CANCER RISK; CASE STUDY; CD4+ T LYMPHOCYTE; CELL MATURATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENDOTHELIUM CELL; ENZYME INHIBITION; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; FETUS DEATH; FOLLOW UP; GENERAL PRACTITIONER; GENETIC POLYMORPHISM; GUILLAIN BARRE SYNDROME; HEART FAILURE; HEART HYPERTROPHY; HEPATITIS B; HEPATITIS C; HISTOPLASMOSIS; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; INCIDENCE; INFECTION RISK; INTERSTITIAL LUNG DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTE; LEUKOCYTOCLASTIC VASCULITIS; LEUKOPENIA; LOW BIRTH WEIGHT; LYMPHOMA; MASS SCREENING; MELANOMA; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NURSE; OFF LABEL DRUG USE; PANCYTOPENIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; PIGMENT EPITHELIUM; PREMATURE LABOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; SPONDYLOARTHROPATHY; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; TH2 CELL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; UVEITIS; UVEORETINITIS; ANTAGONISTS AND INHIBITORS;

ADALIMUMAB; ANTIBODIES, MONOCLONAL; CERTOLIZUMAB PEGOL; ETANERCEPT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84949627910     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2015.06.004     Document Type: Review

References (157)

1. Aeschlimann FA, Hofer K, Schneider EC, et al. A5: detectable anti-infliximab antibodies in children treated with infliximab for rheumatic diseases. Arthritis Rheumatol. 2014;66(Suppl 11):S7.
2. Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in active Behcet uveitis. Am J Ophthalmol. 2006;142:429-34.
3. Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P. Intravitreal adalimumab for refractory uveitisrelated macular edema. Ophthalmology. 2010;117:1612-6.
4. Artornsombudh P, Gevorgyan O, Payal A, Siddique SS, Foster CS. Infliximab treatment of patients with birdshot retinochoroidopathy. Ophthalmology. 2013;120:588-92.
5. Aeschlimann FA, Hofer K, Schneider EC, et al. A5: detectable anti-infliximab antibodies in children treated with infliximab for rheumatic diseases. Arthritis Rheumatol. 2014;66(Suppl 11):S7.
6. Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in active Behcet uveitis. Am J Ophthalmol. 2006;142:429-34.
7. Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P. Intravitreal adalimumab for refractory uveitisrelated macular edema. Ophthalmology. 2010;117:1612-6.
8. Artornsombudh P, Gevorgyan O, Payal A, Siddique SS, Foster CS. Infliximab treatment of patients with birdshot retinochoroidopathy. Ophthalmology. 2013;120:588-92.
9. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2008;20:138-44.
10. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007;66:1339-44.
11. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921-6.
12. Baumgart DC, Grittner U, Steingraber A, Azzaro M, Philipp S. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:2512-20.
13. Beigel F, Schnitzler F, Paul Laubender R, et al. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:91-8.
14. Benitah NR, Sobrin L, Papaliodis GN. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease. Semin Ophthalmol. 2011;26:295-303.
15. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985;229:869-71.
16. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85.
17. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009;68:1177-83.
18. Brunasso AM, Massone C. Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis. J Am Acad Dermatol. 2009;60:781-5.
19. Busch M, Bauer D, Hennig M, Wasmuth S, Thanos S, Heiligenhaus A. Effects of systemic and intravitreal TNFalpha inhibition in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2013;54:39-46.
20. Cai T, Wang Q, Zhou Q, et al. Increased expression of IL-22 is associated with disease activity in Behcet's disease. PLoS One. 2013;8:e59009.
21. Calandra T, Baumgartner JD, Glauser MP. Antilipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock. Prog Clin Biol Res. 1991;367:141-59.
22. Calleja S, Cordero-Coma M, Rodriguez E, Llorente M, Franco M, Ruiz de Morales JG. Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(-) Tregulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study. Eye (Lond). 2012;26:468-77.
23. Calvo-Rio V, Blanco R, Beltran E, et al. Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53:2223-31.
24. Caspi RR. Understanding autoimmune uveitis through animal models. The Friedenwald lecture. Invest Ophthalmol Vis Sci. 2011;52:1872-9.
25. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis. 2009;15:1264-75.
26. Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis. 2010;4:603-5.
27. Chen L, Gordon LK. Ocular manifestations of multiple sclerosis. Curr Opin Ophthalmol. 2005;16:315-20.
28. Chen L, Yang P, Zhou H, et al. Diminished frequency and function of CD4+CD25high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome. Invest Ophthalmol Vis Sci. 2008;49:3475-82.
29. Coffin CS, Fraser HF, Panaccione R, Ghosh S. Liver diseases associated with anti-tumor necrosis factor-alpha (TNFalpha) use for inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:479-84.
30. Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:349-58.
31. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-95.
32. Cordero-Coma M, Calleja S, Llorente M, Rodriguez E, Franco M, Ruiz de Morales JG. Serum cytokine profile in adalimumab-treated refractory uveitis patients: decreased IL-22 correlates with clinical responses. Ocul Immunol Inflamm. 2013;21:212-9.
33. Cordero-Coma M, Calvo-Rio V, Adan A, et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators Inflamm. 2014;2014:717598.
34. Cordero-Coma M, Salom D, Diaz-Llopis M, Lopez-Prats MJ, Calleja S. Golimumab for uveitis. Ophthalmology. 2011;118:1892.e3ee4.
35. Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm. 2013;21:19-27.
36. Danila MI, Patkar NM, Curtis JR, Saag KG, Teng GG. Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr Opin Rheumatol. 2008;20:327-33.
37. de Kozak Y, Cotinet A, Goureau O, Hicks D, Thillaye-Goldenberg B. Tumor necrosis factor and nitric oxide production by resident retinal glial cells from rats presenting hereditary retinal degeneration. Ocul Immunol Inflamm. 1997;5:85-94.
38. de Kozak Y, Naud MC, Bellot J, Faure JP, Hicks D. Differential tumor necrosis factor expression by resident retinal cells from experimental uveitis-susceptible and-resistant rat strains. J Neuroimmunol. 1994;55:1-9.
39. Desai SB, Furst DE. Problems encountered during antitumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-90.
40. Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye (Lond). 2009;23:1868-70.
41. Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575-81.
42. Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun. 1998;11:255-64.
43. Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23:617-37.
44. Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reprod Toxicol. 2011;32:93-7.
45. Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011;13:R105.
46. Durez P, Malghem J, Nzeusseu Toukap A, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007;56:3919-27.
47. Eng G, Stoltenberg MB, Szkudlarek M, et al. Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose. Semin Arthritis Rheum. 2013;43:144-51.
48. Faez S, Lobo AM, Sobrin L, Papaliodis GN. Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clin Experiment Ophthalmol. 2014;42:392-5.
49. Farah RE, Shay MD. Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy. 2007;27:1446-8.
50. Farvardin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina. 2010;30:1530-5.
51. Farvardin M, Afarid M, Shahrzad S. Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther. 2012;28:628-31.
52. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology. 2014;146:681-8.e1.
53. Ferguson TA, Griffith TS. A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev. 2006;213:228-38.
54. Ferguson TA, Griffith TS. The role of Fas ligand and TNFrelated apoptosis-inducing ligand (TRAIL) in the ocular immune response. Chem Immunol Allergy. 2007;92:140-54.
55. Ferraccioli GF, Assaloni R, Perin A. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet. 2002;360:645, author reply 6.
56. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to secondline agents: results of a multinational survey. J Rheumatol. 2007;34:1146-50.
57. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121:437-40.
58. Gallo E, Cabaleiro T, Roman M, et al. The relationship between tumour necrosis factor (TNF)-alpha promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-alpha therapy in psoriasis: a case-control study. Br J Dermatol. 2013;169:819-29.
59. Garcês S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2014;73(6):1138-43.
60. Gaylis NB. Long-term follow-up of an HIV-infected patient with reactive arthritis treated with infliximab. J Clin Rheumatol. 2012;18:153-4.
61. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade). Retina. 2010;30:71-80.
62. Giraudo E, Primo L, Audero E, et al. Tumor necrosis factoralpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem. 1998;273:22128-35.
63. Gomez Reino J, Loza E, Andreu JL, et al. Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients. Reumatol Clin. 2011;7:284-98.
64. Gonzalez-Lopez MA, Blanco R, Gonzalez-Vela MC, Fernandez-Llaca H, Rodriguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis Rheum. 2006;55:817-20.
65. Greiner K, Murphy CC, Willermain F, et al. Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci. 2004;45:170-6.
66. Gupta SR, Phan IT, Suhler EB. Successful treatment of refractory sympathetic ophthalmia in a child with infliximab. Arch Ophthalmol. 2011;129:250-2.
67. Hamam RN, Barikian AW, Antonios RS, et al. Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study. Ocul Immunol Inflamm 2014;1-8.
68. Hamzaoui K, Hamzaoui A, Houman H. CD4+CD25+ regulatory T cells in patients with Behcet's disease. Clin Exp Rheumatol. 2006;24:S71-8.
69. Hangai M, He S, Hoffmann S, Lim JI, Ryan SJ, Hinton DR. Sequential induction of angiogenic growth factors by TNFalpha in choroidal endothelial cells. J Neuroimmunol. 2006;171:45-56.
70. Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol. 2003;21:645-6.
71. Heiligenhaus A, Michels H, Schumacher C, et al. Evidencebased, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32:1121-33.
72. Heller MM, Wu JJ, Murase JE. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J Am Acad Dermatol. 2011;65:870.
73. Imagawa T, Takei S, Umebayashi H, et al. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol. 2012;31:1713-21.
74. Kaburaki T, Araki F, Takamoto M, et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behcet's disease. Graefes Arch Clin Exp Ophthalmol. 2010;248:709-14.
75. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860-4.e2.
76. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res. 2010;35:751-6.
77. Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis. 2012;18:2026-33.
78. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10:4025-31.
79. Kempen JH, Gangaputra S, Daniel E, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol. 2008;146:802-12.e1.
80. Khera TK, Dick AD, Nicholson LB. Mechanisms of TNFalpha regulation in uveitis: focus on RNA-binding proteins. Prog Retin Eye Res. 2010;29:610-21.
81. Kruh JN, Yang P, Suelves AM, Foster CS. Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up. Ophthalmology. 2014;121:358-64.
82. Kump LI, Castaneda RA, Androudi SN, Reed GF, Foster CS. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology. 2006;113:1874-7.
83. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008;159:527-36.
84. Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor-alpha inhibitors. J Rheumatol. 2013;40:1394-403.
85. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785-96.e3.
86. Llorenc V, Mesquida M, Sainz de la Maza M, et al. Certolizumab pegol, a New Anti-TNF-alpha in the armamentarium against ocular inflammation. Ocul Immunol Inflamm 2014;1-6.
87. Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol. 2009;66:490-7.
88. MacEwan DJ. TNF ligands and receptorsda matter of life and death. Br J Pharmacol. 2002;135:855-75.
89. Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214-23, quiz 24.
90. Markomichelakis N, Delicha E, Masselos S, Sfikakis PP. Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet disease: a pilot study in 15 patients. Am J Ophthalmol. 2012;154:534-41.e1.
91. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648-50.
92. Matucci A, Maggi E, Vultaggio A. Cellular and humoral immune responses during tuberculosis infection: useful knowledge in the era of biological agents. J Rheumatol Suppl. 2014;91:17-23.
93. Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther. 2014;40:620-8.
94. Mewar D, Wilson AG. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol. 2011;162:785-91.
95. Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22:90-5.
96. Mohan AK, Edwards ET, Cote TR, Siegel JN, Braun MM. Druginduced systemic lupus erythematosus and TNF-alpha blockers. Lancet. 2002;360:646.
97. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31:1955-8.
98. Moldawer LL. The tumor necrosis factor superfamily and its receptors. Philadelphia, LW&W; 2005.
99. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141-7.
100. Moverley AR, Coates LC, Helliwell PS. Can biologic therapies be withdrawn or tapered in psoriatic arthritis? Clin Exp Rheumatol. 2013;31:S51-3.
101. Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot JF, Bron A. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm. 2011;19:382-3.
102. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye (Lond). 2007;21:824-5.
103. Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 1994;35:3884-9.
104. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-8.
105. Okada AA, Sakai J, Usui M, Mizuguchi J. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm. 1998;6:111-20.
106. Ozdamar Y, Berker N, Bahar G, et al. Inflammatory mediators and posterior segment involvement in ocular Behcet disease. Eur J Ophthalmol. 2009;19:998-1003.
107. Pato E, Munoz-Fernandez S, Francisco F, et al. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum. 2011;40:314-23.
108. Prajapati R, Plant D, Barton A. Genetic and genomic predictors of anti-TNF response. Pharmacogenomics. 2011;12:1571-85.
109. Ramana KV. Tumor necrosis factor-alpha converting enzyme: Implications for ocular inflammatory diseases. Int J Biochem Cell Biol. 2010;42:1076-9.
110. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:529-35.
111. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86:242-51.
112. Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNFtargeted therapies. Best Pract Res Clin Rheumatol. 2008;22:847-61.
113. Reiff A. Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum. 2003;48:2079-80.
114. Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44:1411-5.
115. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum. 2001;44:1977-83.
116. Rocha G, Deschenes J, Cantarovich M. Cyclosporine monitoring with levels 6 hours after the morning dose in patients with noninfectious uveitis. Ophthalmology. 1997;104:245-51.
117. Rubin DT, Panaccione R, Chao J, Robinson AM. A practical, evidence-based guide to the use of adalimumab in Crohn's disease. Curr Med Res Opin. 2011;27:1803-13.
118. Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68:696-701.
119. Sack M. Tumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factoralpha therapy in heart disease. Pharmacol Ther. 2002;94:123-35.
120. Sakaguchi M, Sugita S, Sagawa K, Itoh K, Mochizuki M. Cytokine production by T cells infiltrating in the eye of uveitis patients. Jpn J Ophthalmol. 1998;42:262-8.
121. Sakai T, Watanabe H, Kuroyanagi K, et al. Health-and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis. Br J Ophthalmol. 2013;97:338-42.
122. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factoralpha in clinical uveitis. Ophthalmic Res. 2001;33:251-5.
123. Sartani G, Silver PB, Rizzo LV, et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 1996;37:2211-8.
124. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr. 2006;149:833-6.
125. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's diseasedreview and basis for recommendations. Rheumatology (Oxford). 2007;46:736-41.
126. Sharma SM, Ramanan AV, Riley P, Dick AD. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis. 2007;66:840-1.
127. Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63:612-8.
128. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794.
129. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18-23.
130. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252-7.
131. Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007;125:895-900.
132. Sugita S, Kawazoe Y, Imai A, et al. Role of IL-22-and TNFalpha-producing Th22 cells in uveitis patients with Behcet's disease. J Immunol. 2013;190:5799-808.
133. Sugita S, Yamada Y, Kaneko S, Horie S, Mochizuki M. Induction of regulatory T cells by infliximab in Behcet's disease. Invest Ophthalmol Vis Sci. 2011;52:476-84.
134. Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease. Br J Ophthalmol. 2011;95:549-52.
135. Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, openlabel, prospective trial. Br J Ophthalmol. 2013;97:481-6.
136. Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol. 2009;127:819-22.
137. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903-12.
138. Sun B, Sun SH, Chan CC, Caspi RR. Evaluation of in vivo cytokine expression in EAU-susceptible and resistant rats: a role for IL-10 in resistance? Exp Eye Res. 2000;70:493-502.
139. Sun M, Yang P, Du L, Zhou H, Ren X, Kijlstra A. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2010;51:383-9.
140. Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the longterm efficacy and safety of infliximab treatment for uveitis in Behcet's disease: a multicenter study. Ophthalmology. 2014;121:1877-84.
141. Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol. 2013;40:1749-55.
142. Tornero Molina J, Sanmarti Sala R, Rodriguez Valverde V, et al. Update of the consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis. Reumatol Clin. 2010;6:23-36.
143. Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol. 2008;26:471-5.
144. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244-79.
145. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662-4.
146. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum. 2005;52:2478-84.
147. Umicevic Mirkov M, Cui J, Vermeulen SH, et al. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72:1375-81.
148. Vigano M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther. 2012;12:193-207.
149. Weiss K, Steinbrugger I, Weger M, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye (Lond). 2009;23:1812-8.
150. Wijnen PA, Cremers JP, Nelemans PJ, et al. Association of the TNF-alpha G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J. 2014;43:1730-9.
151. William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritisassociated uveitis. J Ophthalmic Inflamm Infect. 2012;2:231-3.
152. Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:447-58.
153. Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med. 2003;167:1279-82.
154. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol. 2010;94:284-8.
155. Yamada Y, Sugita S, Tanaka H, Kamoi K, Takase H, Mochizuki M. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment. Br J Ophthalmol. 2011;95:205-8.
156. Yeh S, Li Z, Forooghian F, et al. CD4+Foxp3+ T-regulatory cells in noninfectious uveitis. Arch Ophthalmol. 2009;127:407-13.
157. Ziegenhagen MW, Muller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med. 2003;253:18-30.